Commercialisation is a term that is much touted in entrepreneurial circles – although it’s not quite as popular as the term “Investor ready“! It is often titled “New Venture Development”. It stems from the creation of intellectual property (IP) that enables the owner to protect the work to exploit its commercial value.
IP Australia defines Intellectual property (IP) as “the property of your mind or intellect”. It can be an invention, trade mark, original design or the practical application of a good idea”. IP can manifest itself in the following ways:
Copyright;
Trademarks;
Registered Designs;
Patents;
Circuit layout rights;
Plant breeders rights;
Confidential information; and
Trade secrets.
What are the options for commercialisation of IP?
Commercialisation can take many forms depending on what the IP needs to maximise returns for its owners. At its heart is the attempt to maximise the commercial value by converting the IP into a saleable product or service for the benefits of its owners. Generally this involves collaborating with some third party that adds value to the IP and separating the trading entity from the owner of the IP.
The main vehicles for commercialising intellectual property include:
IP Licensing;
IP Sale (Assignment) and subsequent Licensing;
Entering into a Joint Venture;
Mergers and acquisitions; and
Spin out entity.
In all of these cases, there are a minimum of two parties, the IP owner and the party that adds value to the IP by having a market for or having access to a market that will assist to realise the value in the IP.
Licensing
A license is in essence a right to use, therefore, the terms of licence agreements can be diverse. See our article on Licensing Agreements.
Commercialisation is not an exact science. What one person believes is the best way to exploit the inherent value in any particular IP will vary from another persons. Like all things in business there will be competing opinions which all need to be considered.
Further information
Dundas Lawyers is involved in the legal aspects of commercialisation and advises on the law in this area. For further information on how Dundas Lawyers can assist your company with any of its commercialisation needs, contact us for a confidential and obligation-free discussion:
Malcolm Burrows B.Bus.,MBA.,LL.B.,LL.M.,MQLS. Legal Practice Director T: +61 7 3221 0013 (preferred) M: +61 419 726 535 E: mburrows@dundaslawyers.com.au
Disclaimer
This article contains general commentary only. You should not rely on the commentary as legal advice. Specific legal advice should be obtained to ascertain how the law applies to your particular circumstances.
This article examines the concept of implied terms in software contracts, including the requirements for implying a term, the process of determining implied terms, and examples of implied terms applied in software agreements.
The Federal Court of Australia has made a groundbreaking ruling on the patentability of works created by Artificial Intelligence. Explore the implications of this decision and what it could mean for the future of patent law.
The Crimes Legislation Amendment (Ransomware Action Plan) Bill 2022 is set to revolutionize the way cybercrime is prosecuted. Learn more about the changes it brings and the implications they have.
Decentralized autonomous organization (DAO) are a form of digital org on the blockchain, making decisions without centralised management. This article explores their legal grey area, safety and jurisdiction, and the Australian government’s recommendations for a new DAO structure to aid in its governance and success.
From 24 March 2022, any persons with a verified connection to Australia will be able to apply for a domain name ending in .au, also known as a direct name or second level name (Direct Name). Any business can apply for a Direct Name as long as they meet the eligibility criteria under the .au…
Comparative advertising can be a powerful tool, but it must be done within the bounds of the law. Learn more about the legal implications of comparative advertising in Australia, including the case of GlaxoSmithKline Australia Pty Ltd v Reckitt Benckiser (Australia) Pty Limited (No 2) [2018] FCA 1.